GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • S. Karger AG  (2)
  • 1
    Online Resource
    Online Resource
    S. Karger AG ; 2014
    In:  European Addiction Research Vol. 20, No. 2 ( 2014), p. 59-65
    In: European Addiction Research, S. Karger AG, Vol. 20, No. 2 ( 2014), p. 59-65
    Abstract: 〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Attention-deficit hyperactivity disorder (ADHD) is a risk factor for the development of substance use disorders. Treatment of ADHD with psychostimulants in patients on opioid maintenance treatment (OMT) has been restricted in Norway. We examined the use of prescribed drugs for ADHD in OMT patients and assessed co-medication with other psychotropics. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Data were drawn from the nationwide Norwegian Prescription Database (NorPD), which includes all prescriptions filled at pharmacies. The study population included subjects ≥18 years on OMT during 2008-2010. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 In 2010, 6,116 patients received OMT and 2.8% of these also received ADHD drugs. This percentage is seven times greater than that in the gender- and age-specific general population of Norway. The prevalence was higher in the youngest patients, while there was no gender difference. Methylphenidate was the most commonly used drug for ADHD in OMT patients, followed by atomoxetine. 60% of OMT patients filled at least one prescription for antidepressants, anxiolytics or hypnotics, and percentages were similar for users and non-users of ADHD drugs. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Treatment with ADHD drugs was higher in OMT patients than expected from the general population, but was relatively low compared to the prevalence of ADHD in patients with substance use disorders reported in the literature.
    Type of Medium: Online Resource
    ISSN: 1022-6877 , 1421-9891
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2014
    detail.hit.zdb_id: 1482231-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: European Addiction Research, S. Karger AG, Vol. 27, No. 2 ( 2021), p. 131-141
    Abstract: 〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 With recent changes in legislation regulating recreational and medical cannabis use around the globe, increased use in pregnancy is to be expected. 〈 b 〉 〈 i 〉 Objectives: 〈 /i 〉 〈 /b 〉 To investigate the association between cannabis use during pregnancy and birth outcomes. 〈 b 〉 〈 i 〉 Method: 〈 /i 〉 〈 /b 〉 Data from the Norwegian Mother and Child Cohort Study (MoBa), a prospective pregnancy cohort, were used. Participants were recruited from all over Norway between 1999 and 2008: 9,312 women with 10,373 pregnancies who reported use of cannabis before or in pregnancy. Women reported on their illegal drug use before pregnancy and at pregnancy weeks 17/18 and 30 and at 6 months postpartum. Linear regression was used to estimate crude and adjusted effects of prenatal cannabis exposure on birth outcomes. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 In 10,101 pregnancies, women had used cannabis before pregnancy but not during pregnancy. In 272 pregnancies, women had used cannabis during pregnancy, and among these, in 63 pregnancies, women had used cannabis in at least 2 periods. In adjusted analyses for potential confounders, only cannabis use during at least 2 periods of pregnancy showed statistically significant effects on birth weight. The effect was observed in the complete cohort ( 〈 i 〉 B 〈 /i 〉 = −228 g, 95% CI = −354 to −102, 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001) and for the subgroup where information about the child’s father was available ( 〈 i 〉 B 〈 /i 〉 = −225 g, 95% CI = −387 to −63, 〈 i 〉 p 〈 /i 〉 = 0.01). Our results may indicate that prolonged use causes more harm, whereas short-term use did not indicate adverse effects on birth outcomes. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 There was a statistically significant and clinically relevant association between the use of cannabis during pregnancy and reduced birth weight. Clinicians should screen not only for cannabis use but also for the length and intensity of use as part of a comprehensive substance use screening.
    Type of Medium: Online Resource
    ISSN: 1022-6877 , 1421-9891
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2021
    detail.hit.zdb_id: 1482231-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...